Reviva Pharmaceuticals Holdings, Inc. Depreciation
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Depreciation of $0 for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2024-05-14
- Reviva Pharmaceuticals Holdings, Inc. depreciation for the quarter ending 2024-03-31 was $0.00.
- Reviva Pharmaceuticals Holdings, Inc. depreciation for the quarter ending 2023-03-31 was $0.00.
- Reviva Pharmaceuticals Holdings, Inc. depreciation for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. depreciation for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. depreciation for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Reviva Pharmaceuticals Holdings, Inc. depreciation for fiscal 2020 was $591.00, a 8.37% decline from fiscal 2019.
- Reviva Pharmaceuticals Holdings, Inc. depreciation for fiscal 2019 was $645.00.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2024-03-31 | $0.00 10-Q · filed 2024-05-14 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $0.00 derived: sum of 2 quarters · filed 2022-03-15 | $0.00 10-K · filed 2022-03-15 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-16 | |||
| 2020-12-31 | $107.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $269.00 derived: sum of 2 quarters · filed 2022-03-15 | $430.00 derived: sum of 3 quarters · filed 2022-03-15 | $591.00 10-K · filed 2022-03-15 |
| 2020-09-30 | $162.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $323.00 derived: sum of 2 quarters · filed 2021-11-15 | $484.00 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $161.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $322.00 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $161.00 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | $645.00 10-K/A · filed 2021-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |